Life engagement improvements with cariprazine in schizophrenia: a post-hoc analysis of PANSS data from short-term studies

Le résumé fourni par la source

OBJECTIVE: Patient life engagement (PLE) is increasingly recognized as a meaningful treatment goal in schizophrenia, yet it remains under-researched, partly due to the lack of validated PLE measures. This post-hoc analysis evaluated the effect of cariprazine on PLE using a 14-item subset of the Positive and Negative Syndrome Scale (PANSS). METHODS: Data from three 6-week, randomized, double-blind, placebo-controlled trials were pooled and analyzed post-hoc. The 14-item PANSS subset measured PLE across four domains: Cognitive, Social, Emotional, and Physical. Changes from baseline to Week 6 in PLE Total Score and domain scores were analyzed using mixed models for repeated measures. Responder rates (≥5- and ≥ 10-point reductions) were further assessed. RESULTS: Cariprazine (n = 880; 1.5-6.0 mg/day) showed significantly greater improvements than placebo (n = 446) on PLE Total Score (LS mean difference [LSMD] = -3.23; 95% CI: -4.59 to -1.87; Cohen's d = 0.79, P < .001) and across Emotional (LSMD: -0.59; 95% CI: -0.97 to -0.22; Cohen's d = 0.49, P < .001), Social (LSMD: -1.13; 95% CI: -1.65 to -0.6; Cohen's d = 0.71, P < .001), and Cognitive (LSMD: -1.34; 95% CI: -1.91 to -0.76; Cohen's d = 0.77, P < .001) domains, and numerically greater improvement on the Physical (LSMD: -0.25; 95% CI: -0.5 to 0.01; Cohen's d = 0.30, P = .071) domain. Statistically significant improvements emerged by Week 2 on the PLE Total and were sustained through Week 6. Responder analyses showed that 81% and 57% of cariprazine-treated patients met the ≥5- and ≥ 10-point thresholds, respectively, versus 64% and 43% with placebo (both P < .001). CONCLUSION: The results suggest that cariprazine is associated with significant improvements in patient life engagement in schizophrenia based on the 14-item subset of the PANSS, with early and clinically meaningful benefits across domains. These findings support the value of cariprazine in addressing patient-centered treatment goals. Significant outcomes Cariprazine produced significantly greater overall symptom and illness-severity improvements than placebo, with large effect sizes on both PANSS Total (LSMD -7.44) and CGI-S (LSMD -0.41). Cariprazine showed consistently superior reductions in PLE Total and domain scores - especially Social, Cognitive, and Emotional domains - and demonstrated significantly faster and larger weekly improvements from Week 2 onward in PLE Total. Clinically meaningful response rates were higher with cariprazine, with 81% achieving ≥5-point improvement and 57% achieving ≥10-point improvement, both significantly outperforming placebo. Limitations As a post-hoc analysis, it is inherently exploratory and subject to limitations of the original study designs. While recently validated through a robust process, this 14-item subset of the PANSS is a new tool. Its performance over longer time periods, ability to predict functional outcomes, and usefulness across diverse clinical populations still need further investigation. Finally, the studies could not control for external psychosocial factors that may influence life engagement, like participation in psychosocial interventions, caregiver support or follow-up with mental health professionals.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.